Intervencionista
Un ensayo clínico en el que se usa un nuevo medicamento o dispositivo para medir un resultado específico.
ADU-CL-19
A study of BION-1301 in Adults with IgA Nephropathy
Breve descripción
The ADU-CL-19 study is testing BION-1301, an investigational medication that has the potential to reduce proteinuria and preserve kidney function in patients with IgA nephropathy.
Médico del ensayo/Coordinador del estudio
Frank Cortazar
Correo electrónicoNombre del sitio
New York Nephrology
1785 US 9, Suite 102, Clifton Park, NY 12065
Nombre del patrocinador
Chinook Therapeutics, Inc.
Nombre del fármaco del estudio
BION-1301
Matrícula estimada
Up to 40
Fecha estimada de finalización
April 2024
Intervencionista
Un ensayo clínico en el que se usa un nuevo medicamento o dispositivo para medir un resultado específico.
ADU-CL-19
A study of BION-1301 in Adults with IgA Nephropathy
Breve descripción
The ADU-CL-19 study is testing BION-1301, an investigational medication that has the potential to reduce proteinuria and preserve kidney function in patients with IgA nephropathy.
El ensayo es para personas con
Primary IgA Nephropathy (IgAN)
Objetivo del estudio
The goal of this study is to find out whether BION-1301 can safely and tolerably reduce the amount of protein in urine for patients with IgA nephropathy.
Qué implica para el paciente?
Patients will be asked to allow researchers to access medical history, collect blood and urine samples, and perform safety assessments like physical examinations, blood pressure and weight checks, and electrocardiograms. If they are eligible for the study, participants will be asked to come to clinic every 2 weeks for up to 1 year to receive the study drug and, at some visits, collect additional blood and urine samples and safety assessments.
Sobre el medicamento o la intervención
BION-1301 may help reduce proteinuria levels by targeting A-proliferation-inducing ligand (APRIL), a protein that is found in higher levels in people with IgA nephropathy and may worsen their kidney disease. BION-1301 is administered as a subcutaneous (under the skin) injection.